Compass Biotechnologies Performance
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Compass Biotechnologies are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Compass Biotechnologies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong technical and fundamental indicators, Compass Biotechnologies is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Compass |
Compass Biotechnologies Relative Risk vs. Return Landscape
If you would invest 0.00 in Compass Biotechnologies on November 15, 2025 and sell it today you would earn a total of 0.00 from holding Compass Biotechnologies or generate 0.0% return on investment over 90 days. Compass Biotechnologies is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Compass, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Compass Biotechnologies Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Compass Biotechnologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Compass Biotechnologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Compass Biotechnologies is not yet fully synchronised with the market data | |
| Compass Biotechnologies generated a negative expected return over the last 90 days | |
| Compass Biotechnologies has some characteristics of a very speculative penny stock | |
| Compass Biotechnologies has a very high chance of going through financial distress in the upcoming years | |
| Compass Biotechnologies currently holds 78.19 K in liabilities. Compass Biotechnologies has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Compass Biotechnologies' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (323.81 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Compass Biotechnologies currently holds about 31.21 K in cash with (6.45 K) of positive cash flow from operations. | |
| Latest headline from news.google.com: Assessing Compass Therapeutics Valuation After A Year Of Strong Share Price Momentum - simplywall.st |
Compass Biotechnologies Fundamentals Growth
Compass Stock prices reflect investors' perceptions of the future prospects and financial health of Compass Biotechnologies, and Compass Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Compass Stock performance.
| Return On Asset | -0.0336 | |||
| Current Valuation | 288.1 K | |||
| Shares Outstanding | 1.43 B | |||
| Price To Book | 6.47 X | |||
| EBITDA | (708.94 K) | |||
| Cash And Equivalents | 31.21 K | |||
| Total Debt | 78.19 K | |||
| Cash Flow From Operations | (6.45 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 111.67 K | |||
| Retained Earnings | (7.1 M) | |||
About Compass Biotechnologies Performance
By evaluating Compass Biotechnologies' fundamental ratios, stakeholders can gain valuable insights into Compass Biotechnologies' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Compass Biotechnologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Compass Biotechnologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Bangi Inc. acquires and leases various specialized real estate assets to the cannabis industry. Its assets include hemp and cannabis farms, dispensaries, and commercial and industrial real estate properties. BANGI INC is traded on OTC Exchange in the United States.Things to note about Compass Biotechnologies performance evaluation
Checking the ongoing alerts about Compass Biotechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Compass Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Compass Biotechnologies is not yet fully synchronised with the market data | |
| Compass Biotechnologies generated a negative expected return over the last 90 days | |
| Compass Biotechnologies has some characteristics of a very speculative penny stock | |
| Compass Biotechnologies has a very high chance of going through financial distress in the upcoming years | |
| Compass Biotechnologies currently holds 78.19 K in liabilities. Compass Biotechnologies has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Compass Biotechnologies' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (323.81 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Compass Biotechnologies currently holds about 31.21 K in cash with (6.45 K) of positive cash flow from operations. | |
| Latest headline from news.google.com: Assessing Compass Therapeutics Valuation After A Year Of Strong Share Price Momentum - simplywall.st |
- Analyzing Compass Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Compass Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Compass Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Compass Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Compass Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Compass Biotechnologies' stock. These opinions can provide insight into Compass Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Compass Stock
If you are still planning to invest in Compass Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Compass Biotechnologies' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |